Breaking New Ground: Landmark Clinical Trial Opens Islet Cell Transplants to Type 1 Diabetes Patients with Chronic Kidney Disease

In a milestone development for endocrinology and regenerative medicine, a newly launched clinical trial is breaking decades-old medical barriers by offering islet cell transplants to individuals living with both type 1 diabetes (T1D) and chronic kidney disease (CKD). Funded by the global research and advocacy organization Breakthrough T1D, the trial investigates the efficacy and safety of tegoprubart—an investigational immunotherapy developed by Eledon Pharmaceuticals—administered alongside deceased-donor islet cell transplants.

For the first time in medical history, patients suffering from reduced kidney function alongside type 1 diabetes are eligible for a therapeutic pathway that has historically been closed to them due to the severe risks of standard immunosuppressive drugs. According to clinical updates, the first patient enrolled in this groundbreaking study has already successfully received their transplant.

The Opening of a New Frontier in T1D Care

Type 1 diabetes is an autoimmune condition characterized by the destruction of insulin-producing beta cells in the pancreas, requiring lifelong daily insulin administration or advanced technological delivery systems to regulate blood glucose. While islet cell transplantation has emerged over the last two decades as a transformative functional cure capable of restoring natural blood sugar regulation and eliminating the need for daily insulin injections, accessibility has been tightly restricted.

Until now, candidates for islet cell transplants were required to demonstrate robust, healthy kidney function. This restriction stemmed directly from the pharmacological limitations of conventional immunosuppressive regimens, which are strictly mandatory following any cellular or organ transplant to prevent the recipient’s immune system from attacking the foreign tissue. Standard regimens frequently rely on calcineurin inhibitors, most notably tacrolimus. While effective at preventing graft rejection, tacrolimus carries a well-documented, high risk of nephrotoxicity—meaning it can cause significant, cumulative damage to the kidneys.

Because chronic kidney disease is one of the most prevalent and severe long-term microvascular complications associated with type 1 diabetes—affecting roughly 20 to 40 percent of individuals living with the condition—standard transplant protocols automatically disqualified the very patients who often stood to benefit most from restored metabolic control. The introduction of tegoprubart aims to dismantle this long-standing clinical paradox.

The Pharmacology of Tegoprubart: A Targeted Solution

Tegoprubart represents a fundamental shift in post-transplant immunology. Unlike broad-spectrum immunosuppressants that create systemic vulnerability and frequently damage secondary organs, tegoprubart is a targeted monoclonal antibody designed to block specific immunological pathways responsible for cellular rejection.

By interrupting the CD40-CD154 costimulatory pathway, tegoprubart inhibits the activation of T-cells without exerting the toxic side effect profile associated with traditional calcineurin inhibitors. Preclinical data and early-phase clinical evaluations have suggested that tegoprubart can effectively protect transplanted islet cells from immune-mediated destruction while sparing renal tissue from drug-induced injury.

This mechanism forms the backbone of Eledon Pharmaceuticals’ broader clinical strategy. Eledon is currently evaluating tegoprubart in a separate Breakthrough T1D-funded clinical trial involving T1D patients suffering from severe hypoglycemic events or hypoglycemia unawareness—a dangerous condition where patients lose the physical warning signs of plummeting blood sugar. In that ongoing study, participants utilizing tegoprubart-based regimens have successfully achieved complete insulin independence without experiencing the kidney-damaging side effects typical of older protocols. Building upon this foundational success, researchers recognized an opportunity to adapt the protocol for patients whose diminished kidney function previously rendered transplantation impossible.

Trial Design, Logistics, and Participant Criteria

The newly initiated multi-center clinical trial is structured to evaluate up to ten carefully screened participants suffering from type 1 diabetes complicated by chronic kidney disease. The study is being conducted at two premier medical institutions: the University of Chicago and the University of Miami, both of which possess world-renowned transplant and endocrinology divisions.

The experimental protocol replaces traditional nephrotoxic drugs with a calcineurin inhibitor-free immunosuppression regimen centered on tegoprubart alongside deceased-donor islet cell infusions. To determine the success of the intervention, investigators have established rigorous primary endpoints to be evaluated one year post-transplant. These metrics include:

• Achievement of complete insulin therapy independence.
• Sustained HbA1c levels of less than 7%.
• Total absence of severe hypoglycemic episodes, verified rigorously through continuous glucose monitoring (CGM) technology.

Financial backing for the trial is substantial. Breakthrough T1D awarded an $8.5 million research grant directly to the University of Chicago to underwrite the clinical operations and scientific analysis of the study. Furthermore, therapeutic developer Eledon Pharmaceuticals operates within the investment portfolio of the T1D Fund, establishing a collaborative ecosystem of philanthropic research funding and commercial biotechnology development dedicated to curing the condition.

Institutional Perspectives and Strategic Implications

The launch of the trial is a centerpiece of Breakthrough T1D’s broader strategic initiative known as Project ACT, an organizational commitment designed to accelerate the clinical translation of beta-cell replacement therapies and expand patient access globally.

"Advancing promising islet cell research that is a next step toward durable and scalable cures for type 1 diabetes is a key priority for Breakthrough T1D," stated Esther Latres, Ph.D., Senior Vice President of Research at Breakthrough T1D. "We’re proud to support this trial that expands cell therapy research and access to people living with T1D and chronic kidney disease for the first time."

Medical analysts and researchers point out that if the trial meets its primary endpoints, the ramifications for the diabetes community will be profound. By removing the kidney exclusion criteria, thousands of patients previously sidelined by organ complications could become viable candidates for islet transplantation.

The ultimate long-term objective shared by researchers, biotech developers, and advocacy groups is the total elimination of heavy immunosuppression requirements. Achieving this milestone would transform islet cell transplantation from a specialized procedure reserved for a narrow subset of patients into a widely accessible, scalable therapy available to any individual living with type 1 diabetes, regardless of their secondary medical complications.

As the first enrolled patient progresses through the critical post-transplant observation window, the medical community will watch closely. The outcome of this trial may well redefine the standard of care for advanced type 1 diabetes, turning a once-impossible therapeutic bridge into an established clinical reality.